Evidence map›Paper›PMID 33322409›Full record

ArticlePharmaceuticals (Basel, Switzerland)2020

Antimicrobial, Anticancer and Multidrug-Resistant Reversing Activity of Novel Oxygen-, Sulfur- and Selenoflavones and Bioisosteric Analogues.

Małgorzata Anna Marć, Annamária Kincses, Bálint Rácz, Muhammad Jawad Nasim, Muhammad Sarfraz, Carlos Lázaro-Milla, Enrique Domínguez-Álvarez, Claus Jacob, Gabriella Spengler, Pedro Almendros

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Triterpenes fromJournal of natural products · 2022
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Małgorzata Anna MarćDepartment of Medical Microbiology and Immunobiology, University of Szeged, H-6720 Szeged, Hungary.ORCID 0000-0002-5183-801X
Annamária KincsesDepartment of Medical Microbiology and Immunobiology, University of Szeged, H-6720 Szeged, Hungary.ORCID 0000-0002-1591-1419
Bálint RáczDepartment of Medical Microbiology and Immunobiology, University of Szeged, H-6720 Szeged, Hungary.
Muhammad Jawad NasimDivision of Bioorganic Chemistry, School of Pharmacy, Saarland University, D-66123 Saarbruecken, Germany.ORCID 0000-0003-2911-2607
Muhammad SarfrazDivision of Bioorganic Chemistry, School of Pharmacy, Saarland University, D-66123 Saarbruecken, Germany.
Carlos Lázaro-MillaGrupo de Lactamas y Heterociclos Bioactivos, Unidad Asociada al CSIC, Departamento de Química Orgánica I, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.ORCID 0000-0003-3698-1405
Enrique Domínguez-ÁlvarezInstituto de Química Orgánica General IQOG-CSIC, Consejo Superior de Investigaciones Científicas, Juan de la Cierva 3, 28006 Madrid, Spain.ORCID 0000-0003-2655-1575
Claus JacobDivision of Bioorganic Chemistry, School of Pharmacy, Saarland University, D-66123 Saarbruecken, Germany.ORCID 0000-0002-6288-7220
Gabriella SpenglerDepartment of Medical Microbiology and Immunobiology, University of Szeged, H-6720 Szeged, Hungary.ORCID 0000-0001-8085-0950
Pedro AlmendrosInstituto de Química Orgánica General IQOG-CSIC, Consejo Superior de Investigaciones Científicas, Juan de la Cierva 3, 28006 Madrid, Spain.ORCID 0000-0001-6564-2758
University of Szeged · HUSaarland University · DEConsejo Superior de Investigaciones Científicas · ESUniversidad Complutense de Madrid · ES

Funding

Agencia Estatal de Investigacion (AEI) del MICIU (Spain); FEDER PGC2018-095025-B-I00Consejo Superior de Investigaciones Científicas (CSIC) LINKA20285State of Hungary GINOP-2.3.2-15-2016-00038
6 · The paper itself

Abstract

Multidrug resistance of cancer cells to cytotoxic drugs still remains a major obstacle to the success of chemotherapy in cancer treatment. The development of new drug candidates which may serve as P-glycoprotein (P-gp) efflux pump inhibitors is a promising strategy. Selenium analogues of natural products, such as flavonoids, offer an interesting motif from the perspective of drug design. Herein, we report the biological evaluation of novel hybrid compounds, bearing both the flavone core (compounds

Indexed as

antimicrobialcancerflavonoidsMDR efflux pumpsmultidrug resistance (MDR)nematicidal activityP-glycoprotein (P-gp) efflux pumpseleniumsulfur

Identifiers

PMID33322409
PMCPMC7763008
OpenAlexW3112343493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.